Actemra Actpen Injection, Solution
Product Images NDC 50242-143

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Actemra Actpen (NDC 50242-143). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Actemra 01)

Line graph showing the percentage of ACR20 responders over time from week 2 to week 24. The graph compares three treatment groups: Placebo + MTX, ACTEMRA 4 mg/kg + MTX, and ACTEMRA 8 mg/kg + MTX, with ACTEMRA groups showing higher response percentages than placebo. The x-axis represents the visit weeks, and the y-axis shows the percentage of responders with standard error bars.*

FDA Label Image

Figure 2 (Actemra 01a)

A line graph showing change from baseline in FVC (L) over 48 weeks. Two treatment groups are compared: PBO 162 mg subcutaneous (SC), represented by triangles and a dashed line; and TCZ 162 mg SC, represented by circles and a dotted line. Data points include error bars indicating variability at each time point (8, 16, 24, 36, and 48 weeks).*

FDA Label Image

Figure 3 (Actemra 01b)

A forest plot chart depicting risk differences and 95% confidence intervals for deaths across four studies comparing SOC (standard of care) to Actemra plus SOC. Each study is listed with total patients, deaths, and percentages for each group. The plot shows whether the data favors Actemra plus SOC or SOC alone, summarizing an overall risk difference with confidence interval at the bottom.*

FDA Label Image

Figure A (Actemra 02)

An instructional diagram showing the parts of an ACTEMRA 162 mg pre-filled syringe before and after use. It labels the needle cap, expiration date on the syringe barrel, trigger fingers to avoid touching, plunger, and the needle-shield which is extended and locked after use to prevent needle exposure.*

FDA Label Image

Figure B (Actemra 03)

Illustration showing a sharps disposal container labeled 'Sharps Disposal,' two alcohol pads, a sterile cotton ball, and an ACTEMRA prefilled syringe, representing components for injection preparation and administration.*

FDA Label Image

Figure C (Actemra 04)

An instructional illustration showing a hand holding an injection pen or syringe-like device, with a focus highlighted on the tip or needle area, next to an image of an eye. The diagram suggests inspecting the device closely, possibly for clarity or presence of liquid before administration.*

FDA Label Image

Figure D (Actemra 05)

An illustration showing recommended injection sites for ACTEMRA (tocilizumab) at the front and back of a human body. Shaded areas indicate injection sites on the abdomen and thigh for the front view, and the upper arm for the back view.*

FDA Label Image

Figure E (Actemra 06)

An instructional illustration showing hands holding a syringe and a cap. The image depicts the removal of the syringe cap, indicated by an arrow pointing away from the cap, to prepare the injection device for use.*

FDA Label Image

Figure F (Actemra 07)

Illustration showing a hand holding a syringe, positioned to demonstrate proper handling or injection technique. The syringe appears to be prepared for intravenous administration.*

FDA Label Image

Figure G (Actemra 08)

An instructional illustration showing a hand administering an injection perpendicularly at 90 degrees into the skin, marked as OK. An inset circle contrasts this with an incorrect angle injection at 45 degrees. This diagram demonstrates the proper angle for an intramuscular or subcutaneous injection technique for the ACTEMRA injection solution concentrate.*

FDA Label Image

Figure H (Actemra 09)

An instructional illustration showing a hand holding a syringe or injection device perpendicular to a surface, likely demonstrating the correct angle and position for administering an injection, related to ACTEMRA (tocilizumab) intravenous injection.*

FDA Label Image

Figure I (Actemra 10)

An instructional illustration showing a hand holding a syringe for an injection, positioned vertically with the needle pointing downward toward an injection site on the skin. The image demonstrates the correct orientation for administering an injection.*

FDA Label Image

Figure J (Actemra 11)

Illustration showing a hand holding a syringe-like device with an upward arrow indicating removal of a cap or cover. This diagram likely demonstrates a step in preparing the ACTEMRA injection solution for intravenous use.*

FDA Label Image

Figure K (Actemra 12)

An instructional illustration showing a hand disposing of a syringe into a designated sharps container. The image demonstrates safe disposal of injection equipment, relevant for intravenous administration of medications such as ACTEMRA (tocilizumab) injection solution concentrate.*

FDA Label Image

Figure A (Actemra 13)

An instructional diagram showing the ACTEMRA 162 mg prefilled syringe injection before and after use. The image highlights key parts such as the green activation button, expiration date, window area, needle shield, and green cap before use. After use, the needle shield is extended and locked, and a purple "injection complete" indicator is visible.*

FDA Label Image

Figure B (Actemra 14)

An instructional illustration showing disposal and preparation items for ACTEMRA ACTPen autoinjector. It features a labeled sharps disposal container, two alcohol pads, a sterile cotton ball, and the ACTEMRA ACTPen autoinjector showing a visible label with the name and strength (162 mg). This diagram highlights key components involved in the injection process.*

FDA Label Image

Figure C (Actemra 15)

Illustration labeled Figure C depicting a hand holding a test tube or vial with a fingerprint on the bottom. A beam of light or sightline projects from an eye toward the fingerprint, indicating a focus or inspection of the fingerprint in the container.*

FDA Label Image

Figure D (Actemra 16)

An instructional diagram showing suggested injection sites for a medication. The front view highlights areas on the abdomen and thighs, while the back view highlights areas on the upper arms. Injected sites are marked in dark gray.*

FDA Label Image

Figure E (Actemra 17)

An instructional illustration showing a hand removing a green cap from a vial or injection bottle by twisting. A close-up inset highlights the green cap and notes a loose fitting metal tube beneath it. The diagram explains part of the preparation or usage process for ACTEMRA (tocilizumab) injection solution concentrate.*

FDA Label Image

Figure F (Actemra 18)

An instructional illustration labeled Figure F showing a hand gripping an injection pen or syringe vertically, demonstrating proper holding technique likely related to administering Actemra (tocilizumab) injection solution.*

FDA Label Image

Figure G (Actemra 19)

An instructional illustration labeled Figure G showing a hand pinching the skin of a person's arm, likely demonstrating a technique related to injection preparation or administration.*

FDA Label Image

Figure H (Actemra 20)

An instructional illustration labeled Figure H showing a hand positioned to administer an injection at a 90-degree angle. The image indicates the correct angle for intravenous injection, with an arrow pointing downward from a syringe toward the skin.*

FDA Label Image

Figure I (Actemra 21)

An instructional diagram showing a hand holding an injection device (likely a syringe or autoinjector) with a close-up on the locking mechanism before and after unlocking. The image depicts how to unlock the device by releasing the lock on the injection mechanism.*

FDA Label Image

Figure J (Actemra 22)

An instructional diagram labeled Figure J shows a hand pressing down on an injection pen or device, indicating the action "click" at the start. The device appears to be positioned on a surface, likely skin, to demonstrate proper use.*

FDA Label Image

Figure K (Actemra 23)

An instructional illustration labeled Figure K showing a hand holding a prefilled syringe vertically against skin. The image emphasizes to hold and watch for 10 seconds after injection, indicated by an eye icon and a stopwatch icon with '10 seconds' text.*

FDA Label Image

Figure L (Actemra 24)

An instructional illustration labeled "Figure L" showing a hand holding an injection device vertically above a surface with an upward arrow indicating motion or direction. This figure likely demonstrates a step in the usage or administration of ACTEMRA (tocilizumab) injection.*

FDA Label Image

Figure M (Actemra 25)

Illustration showing a hand holding a syringe labeled ACTEMRA (tocilizumab) injection solution, concentrating on administration or disposal technique involving insertion into a container.*

FDA Label Image

Principal Display Panel (80 mg/4 mL Vial Carton)

The label for Actemra (tocilizumab) injection, solution concentrate for intravenous use shows the strength 80 mg/4 mL (20 mg/mL). It is a single-dose vial with no preservative. The label includes the NDC 50242-135-01 and the Genentech logo, along with important usage instructions and medication guide information for providers.*

FDA Label Image

Principal Display Panel (200 mg/10 mL Vial Carton)

Actemra (tocilizumab) injection 200 mg/10 mL (20 mg/mL) solution concentrate for intravenous infusion. Label includes dosage instructions, single-dose vial use, and provider attention regarding the medication guide. Labeler is Genentech, Inc.*

FDA Label Image

Principal Display Panel (400 mg/20 mL Vial Carton)

Label for Actemra (tocilizumab) Injection, concentrate for intravenous infusion. The strength shown is 400 mg per 20 mL (20 mg/mL), in a single-dose vial. The label indicates no preservative and includes usage cautions. Manufactured by Genentech, Inc.*

FDA Label Image

Principal Display Panel (162 mg/0.9 mL Prefilled Syringe Carton)

Actemra (tocilizumab) Injection 162 mg/0.9 mL prefilled syringe label for subcutaneous injection only. The label indicates single dose use and instructs to discard unused portion. It includes pharmacist attention for providing medication guide and refrigeration instructions. Manufactured by Genentech, Inc.*

FDA Label Image

Principal Display Panel (162 mg/0.9 mL Autoinjector Carton)

Actemra ACTPen (tocilizumab) Injection 162 mg/0.9 mL single-dose autoinjector label. It is for subcutaneous injection only, sterile, and includes storage instructions to refrigerate immediately. The label features a caution note and an illustration showing the injection completion indicated by a purple indicator stopping. Labeler is Genentech, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.